Iosif Gershteyn
Founder & Chief Executive Officer Immuvia
Iosif M. Gershteyn is the Founder and Chief Executive Officer of ImmuVia, the company developing the Cancerlysin™ platform – a class of payload-free bispecific antibodies that achieve tumor-selective extrinsic apoptosis through antigen-guided DR5 superclustering. ImmuVia’s lead program, IMV-M™ (MUC16×DR5), is in IND-enabling development for ovarian, pancreatic, and non-small cell lung cancers, with Dr. Daniel Von Hoff as Phase 1 PI. The Cancerlysin™ franchise is being built by scientific leadership behind Kadcyla®, Elahere®, and Sarclisa®. Prior to ImmuVia, Iosif founded several scientifically focused ventures and held earlier roles in asset management and M&A strategy. He has published across computational immunology, antibody engineering, and neuroscience.
Seminars
- Why ADCs hit a ceiling: Payload-driven toxicity narrows therapeutic windows and confines benefit to high-antigen-expressing tumors. Even leading approved programs struggle to reach the moderate- and low-expressing patients who often make up most of the addressable population
- The Cancerlysin™ Solution: Antigen-guided DR5 superclustering. MUC16 binding by IMV-M™ triggers tumor-localized DR5 superclustering and extrinsic apoptotic signaling with no cytotoxic payload. Single-agent regressions in pancreatic, lung, and ovarian xenograft models; clean NHP safety to 4× therapeutic dose with zero hepatotoxicity; projected patient eligibility of 50% in NSCLC and 64–92% in ovarian – multiples over leading DXd-ADCs in the same indications
- A platform built for what comes after ADCs. The Cancerlysin™ platform extends to IMV-C (colorectal, gastric) and IMV-5 (AML); its payload-free architecture is compatible with standard antibody manufacturing – no linker chemistry, no DAR control, no payload-related regulatory burden
